CONMED (CNMD) Q4 2025 earnings review
Orthopedics Resurges, But Strategic Reset Weighs on 2026 Outlook
CONMED delivered a strong finish to 2025, with Q4 revenue accelerating to 7.9% growth, driven by a massive recovery in Orthopedics (+13.2%) and surging International demand (+17.0%). However, the narrative is complicated by a strategic reset: the company is divesting its Gastroenterology (GI) business and transitioning its CFO. While the underlying organic growth forecast of 4.5-6% for 2026 is healthy, the divestiture creates a reported earnings hole, causing FY26 EPS guidance ($4.30-$4.45) to drop below FY25 actuals ($4.59).
🐂 Bull Case
The supply chain nightmare in Orthopedics appears over. After growing less than 1% in Q2, the segment surged 13.2% in Q4, validating management's turnaround efforts and signaling share recapture is underway.
International markets are outperforming significantly, growing 17.0% as reported (15.4% constant currency) in Q4. This diversification reduces reliance on the slower-growing (1.4%) domestic market.
🐻 Bear Case
The exit from the GI business creates significant dilution. FY26 Adjusted EPS guidance of $4.30-$4.45 implies a YoY decline from FY25's $4.59. Investors face a transition year with shrinking bottom-line numbers.
Despite higher sales volume, Adjusted Gross Margin compressed to 56.6% in Q4 from 57.6% a year ago. Inflationary pressures and product mix shifts are preventing revenue leverage from flowing to the bottom line.
⚖️ Verdict: ⚪
Neutral. The operational turnaround in Orthopedics is undeniably impressive, but the investment thesis is muddied by the GI divestiture, a CFO transition, and guidance that implies an earnings decline in 2026. CONMED is a 'show me' story for the next 12 months.
Key Themes
Orthopedic Segment Acceleration
Accelerating. The most critical data point in this report is the V-shaped recovery in Orthopedics. After struggling with backorders throughout early 2025 (hitting a low of 0.9% growth in Q2), the segment delivered 13.2% growth in Q4. This confirms that supply chain remediation efforts were successful and the sales force is effectively recapturing demand.
International Outperformance
Accelerating. International revenue growth accelerated to 17.0% reported in Q4 from 7.8% in Q3. In Constant Currency, International grew 15.4% vs Domestic growth of just 1.4%. The company is effectively leveraging its product portfolio globally to offset softer US growth rates.
Strategic Reset: GI Divestiture & CFO Departure
CONMED announced the exit of its Gastroenterology business (approx. $80M annual revenue) and the departure of CFO Todd Garner in March 2026. While the GI exit aligns resources with higher-growth areas, it creates a near-term revenue hole and an estimated ~$0.48 headwind to 2026 EPS. Executive turnover adds execution risk during this transition.
GAAP Profitability Volatility
GAAP Net Income fell 50% YoY in Q4 ($16.7M vs $33.8M). This was driven by significant 'Other Expenses,' including a $19.4M contingent consideration fair value adjustment and costs related to terminating a distribution agreement. While Adjusted EPS rose, the quality of earnings is impacted by these recurring 'one-time' adjustments.
Margin Pressure Persists
Despite the volume surge, Adjusted Gross Margin fell 100 basis points YoY to 56.6%. The company cited mix and inflationary costs. Furthermore, Operating Margin (GAAP) compressed to 9.8% from 15.2% a year prior. Efficiency gains from higher sales are being consumed by costs and adjustments.
Other KPIs
Stable. Adjusted EBITDA margin came in at 21.5%, slightly down from 23.1% in the prior year period. While absolute dollars were flat ($80.4M vs $80.0M), the margin compression highlights the difficulty in converting top-line beats into profit growth.
Reversing. After shrinking -15.5% in Q2 and growing only 6% in Q3, Capital Products grew 8.2% reported (7.3% CC) in Q4. This indicates a healthier hospital capex environment and improved availability of equipment.
Accelerating. Recurring revenue grew 7.8%, up from 6.3% in Q3. This high-quality revenue stream now constitutes roughly 86% of total sales, providing stability.
Guidance
Decelerating/Negative. The guidance range is effectively flat to down vs 2025 actuals ($1.375B). However, this includes the removal of ~$80M from the GI divestiture. Organic constant currency growth is guided at 4.5% to 6.0%, which is stable relative to 2025 performance.
Reversing. This represents a decline from the $4.59 achieved in 2025. The drop is primarily due to the GI divestiture (approx. -$0.48 impact) and tariff headwinds (-$0.30 to -$0.35 incremental). Organic operational growth is insufficient to offset these structural headwinds in the near term.
The company forecasts significant incremental tariff costs in 2026, weighing heavily on profitability. This is a major factor in the EPS guidance decline.
Key Questions
Orthopedic Demand Durability
The Q4 jump in Orthopedics to 13% growth was spectacular. How much of this was 'catch-up' shipping from prior backorders versus sustainable underlying demand, and what is the normalized growth rate for this segment in 2026?
Margin Bridge for 2026
With the high-margin GI business being divested and tariff headwinds of $0.30-$0.35, can you walk us through the gross margin bridge for 2026? Are there cost savings initiatives sufficient to offset these structural hits?
Domestic Weakness
Domestic revenue grew only 1.4% in Q4 while International soared 17%. What is causing the sluggishness in the US market—is it purely the lingering effect of Ortho supply issues, or are you seeing competitive pressure or hospital spending fatigue?
GI Divestiture Rationale
Given the immediate earnings dilution, what specifically does the GI exit unlock for the company strategically? Are the proceeds earmarked for debt paydown or M&A?